Ming H Cheng

US Patent:

20180127503, May 10, 2018

Filed:

Mar 10, 2016

Appl. No.:

15/555036

Inventors:

- Emeryville CA, US
- New York NY, US
Pei WANG - Union City CA, US
Nai-Kong CHEUNG - Purchase NY, US
Hongfen GUO - Forest Hills NY, US
Ming CHENG - Roosevelt Island NY, US

International Classification:

C07K 16/28
C07K 16/22
A61K 47/68
A61P 35/00

Abstract:

The invention relates to antibodies, and in particular, to antibodies exhibiting specificity for Receptor tyrosine kinase-like Orphan Receptors (ROR), and to uses thereof for example in the treatment of cancer. The invention extends to polynucleotide and polypeptide sequences encoding the antibodies, and therapeutic uses thereof, and to diagnostic kits comprising these molecules. The invention also extends to antibody-drug conjugates and to uses thereof in therapy.

US Patent:

20170342151, Nov 30, 2017

Filed:

Nov 12, 2015

Appl. No.:

15/526309

Inventors:

- New York NY, US
- Boston MA, US
Ming Cheng - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY
The General Hospital Corporation - Boston MA

International Classification:

C07K 16/28
C07K 16/44
C07K 16/30
A61K 39/00

Abstract:

Described herein are antibodies that bind chondroitin sulfate proteoglycan 4 (CSPG4) and, in particular, chimeric and humanized anti-CSPG4 antibodies and fragments thereof. Also provided herein are methods of using individual humanized antibodies or compositions thereof for the detection, prevention, and/or therapeutic treatment of CSPG4-related diseases, in particular, melanoma.